We use long RNA biomarkers to enable precise patient-to-targeted therapy matching
We use long RNA biomarkers to enable precise patient-to-targeted therapy matching
About us
Wobble Genomics is building the next-generation RNA platform for precision medicine. We enable pharmaceutical and diagnostics companies to access deeper biological insight, improving target identification, patient stratification, and clinical success rates.
Current sequencing approaches miss critical RNA variation, leaving gaps in our understanding of disease. Wobble’s platform captures full-length RNA transcripts, revealing actionable biology that standard methods cannot detect.
Our approach supports applications across biomarker discovery, diagnostics, and therapeutic development, helping partners make better decisions, faster.

About us

Wobble Genomics is building the next-generation RNA platform for precision medicine. We enable pharmaceutical and diagnostics companies to access deeper biological insight, improving target identification, patient stratification, and clinical success rates.
Current sequencing approaches miss critical RNA variation, leaving gaps in our understanding of disease. Wobble’s platform captures full-length RNA transcripts, revealing actionable biology that standard methods cannot detect.
Our approach supports applications across biomarker discovery, diagnostics, and therapeutic development, helping partners make better decisions, faster.
What we do
Improve Clinical Success
Identify more precise biomarkers to optimise patient selection and trial design.
Unlock New Targets
Reveal novel RNA isoforms and disease-specific targets for next-generation therapies.
Enable Better Diagnostics
Support the development of more accurate, clinically relevant diagnostic tools.
Why it matters
Most drug failures are driven by incomplete biology. By providing a more complete and actionable view of RNA, Wobble Genomics helps reduce risk, accelerate development timelines, and improve outcomes across the drug development pipeline.
What we do
Improve Clinical Success
Identify more precise biomarkers to optimise patient selection and trial design.
Unlock New Targets
Reveal novel RNA isoforms and disease-specific targets for next-generation therapies.
Enable Better Diagnostics
Support the development of more accurate, clinically relevant diagnostic tools.
Why it matters
Most drug failures are driven by incomplete biology. By providing a more complete and actionable view of RNA, Wobble Genomics helps reduce risk, accelerate development timelines, and improve outcomes across the drug development pipeline.

